Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Vietnam Investment Review on MSN2d
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular CarcinomaLion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.
China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy ...
Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback